Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and Gilead Sciences (GILD)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Establishment Labs Holdings (ESTA) and Gilead Sciences (GILD) with bullish sentiments.
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
Establishment Labs Holdings (ESTA)
TD Cowen analyst Josh Jennings reiterated a Buy rating on Establishment Labs Holdings yesterday and set a price target of $95.00. The company’s shares closed last Thursday at $85.11.
According to TipRanks.com, Jennings is a 3-star analyst with an average return of
Currently, the analyst consensus on Establishment Labs Holdings is a Strong Buy with an average price target of $89.50.
See the top stocks recommended by analysts >>
Gilead Sciences (GILD)
Wells Fargo analyst Mohit Bansal maintained a Buy rating on Gilead Sciences yesterday and set a price target of $165.00. The company’s shares closed last Thursday at $125.87.
According to TipRanks.com, Bansal is a 5-star analyst with an average return of
Currently, the analyst consensus on Gilead Sciences is a Strong Buy with an average price target of $160.11, a 31.5% upside from current levels. In a report issued on June 2, Bank of America Securities also maintained a Buy rating on the stock with a $162.00 price target.
Read More on ESTA:
Disclaimer & DisclosureReport an Issue
- Establishment Labs Shareholders Reaffirm Board, Pay and Auditor
- Establishment Labs Signals Strong Momentum in Q1 Call
- Establishment Labs Signals Strong Momentum in Earnings Call
- Buy Rating Reaffirmed on Strong Growth Outlook and Pipeline Momentum; $90 Price Target Unchanged
- Establishment Labs price target raised to $90 from $88 at BTIG
